Home › Funds › Lion Point Capital, LP › FENC
Lion Point Capital, LP position in FENC
FENNEC PHARMACEUTICALS INC COM · Health Care
Lion Point Capital, LP reported holding 112,434 shares of FENC (FENNEC PHARMACEUTICALS INC COM) in its Q2 2026 13F filing — a position valued at US$1.2M, representing 5.78% of its reported portfolio and ranking #4 among its reported holdings. Lion Point Capital, LP has disclosed FENC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's FENC position evolved
Lion Point Capital, LP first disclosed a stake in FENC in Q3 2023 at 110,000 shares (US$826K). The position peaked in Q1 2024 at 170,000 shares, worth US$1.9M. Across 12 filings, Lion Point Capital, LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 112,434 shares valued at US$1.2M. Notable position changes include a 55% increase in Q1 2024 (shares fell 45% over the following quarter), a 26% increase in Q3 2024 (shares rose 26% over the following quarter), a 37% trim in Q3 2025 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 110.00K | $826.10K | New |
| Q4 2023 | 110.00K | $1.23M | Hold |
| Q1 2024 | 170.00K | $1.89M | Add |
| Q2 2024 | 170.00K | $1.04M | Hold |
| Q3 2024 | 215.00K | $1.07M | Add |
| Q4 2024 | 195.70K | $1.24M | Reduce |
| Q1 2025 | 195.70K | $1.19M | Hold |
| Q2 2025 | 195.70K | $1.62M | Hold |
| Q3 2025 | 123.00K | $1.15M | Reduce |
| Q4 2025 | 112.43K | $865.74K | Reduce |
| Q1 2026 | 112.43K | $691.47K | Hold |
| Q2 2026 | 112.43K | $1.21M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FENC and 13F data
FENC (FENNEC PHARMACEUTICALS INC COM) is a Health Care company. 52 other funds we track also report a position in FENC — the largest reported positions include Rosalind Advisors, Inc. (US$34.3M), AIGH Capital Management LLC (US$26.7M), Solas Capital Management, LLC (US$20.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FENC
- Rosalind Advisors, Inc. 3.19M sh · $34.27M · Q2 2026
- AIGH Capital Management LLC 2.49M sh · $26.72M · Q2 2026
- Solas Capital Management, LLC 1.89M sh · $20.31M · Q2 2026
- AWM Investment Company, Inc. 1.16M sh · $12.47M · Q2 2026
- Prospect Capital Advisors, LLC 497.80K sh · $5.35M · Q2 2026
- Potomac Capital Management, Inc. 224.40K sh · $2.41M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held FENC?
Lion Point Capital, LP has disclosed FENC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Lion Point Capital, LP's current position in FENC?
As of Q2 2026, Lion Point Capital, LP holds 112.43K shares of FENC (FENNEC PHARMACEUTICALS INC COM), valued at $1.21M, representing 5.78% of its reported portfolio and ranking #4.
Has Lion Point Capital, LP been buying or selling FENC?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in FENC. The position peaked in Q1 2024 at 170.00K shares.
Which other funds hold FENC?
Other major institutional holders of FENC include Rosalind Advisors, Inc., AIGH Capital Management LLC, Solas Capital Management, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.